Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Could Face Damages Of $1.2 Billion For At-Risk Launch Of Generic Protonix

This article was originally published in The Pink Sheet Daily

Executive Summary

A jury finds that Pfizer's patent on the proton pump inhibitor is valid; analyst Timothy Anderson estimates that without a settlement Teva's damages could top $1 billion but thinks the actual impact will be smaller.
Advertisement

Related Content

Protonix Settlement Leaves Question Of How Jury Would Assess At-Risk Launch Damages
Protonix Settlement Leaves Question Of How Jury Would Assess At-Risk Launch Damages
AstraZeneca, Korea’s Hanmi Move To Appellate Court In Nexium Patent Dispute
AstraZeneca, Korea’s Hanmi Move To Appellate Court In Nexium Patent Dispute
At-Risk Launches: Three Cases May Determine How Damages Are Calculated
At-Risk Launches: Three Cases May Determine How Damages Are Calculated
Famvir Patent Settlement: 17 Months After At-Risk Launch, Teva Must Pay Novartis
Famvir Patent Settlement: 17 Months After At-Risk Launch, Teva Must Pay Novartis
Bundling of Wyeth Protonix Sales to Hospitals Tied to Medicaid Fraud, DoJ Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS070548

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel